First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the arbeitsgemeinschaft gynakologische onkologie ovarian cancer study group

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 46-51

  Du Bois, Andreas ^a   Luck H J ^a   Bauknecht, T ^a   Meier, W ^a   Richter, B ^a   Kuhn W ^a   Quaas, J ^a   Pfisterer, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAXIMUM ALLOWABLE CONCENTRATION; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA;

EID: 0345251967     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.46     Document Type: Article

References (28)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Stuart G, Bertelsen K, Mangioni C, et al: Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottishinter-group trial. Proc Am Soc Clin Oncol 17:361a, 1998 (abstr 1394)
3. du Bois A, Richter B, Warm M, et al: Cisplatin/paclitaxel vs carboplatin/paclitaxel as 1st-line treatment in ovarian cancer. Proc Am Soc Clin Oncol 17:361a, 1998 (abstr 1395)
4. Neijt JP, Hansen M, Hansen SW, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1259)
5. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668-1674, 1991
6. A'Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 45:726-732, 1995
7. Fanning J, Bennett TZ, Hilgers RD: Metaanalysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80:954-960, 1992
8. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
9. Vermorken JB, Kobierska A, van der Burg MEL, et al: High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: The EORTC-GCCG experience. Eur J Gynaec Oncol 16:433-438, 1995
10. Homesley HD, Harry DS, O'Toole RV, et al: Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. Am J Clin Oncol 15:129-134, 1992
11. Gehl J, Boesgard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7:687-693, 1996
12. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
13. Lück HJ, du Bois A, Thomssen C, et al: Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer. Oncology 11:34-37, 1997 (suppl 3)
14. Conte PF, Baldini E, Gennari A, et al: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15:2510-2517, 1997
15. Calvert AH, Newell DR, Gumbrell LA: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 17:1748-1756, 1989
16. Jeliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604, 1973 (letter)
17. du Bois A, Lück HJ, Bauknecht T, et al: Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 8:355-361, 1997
18. National Cancer Institute common toxicity criteria, in Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins, 1990, pp 1133-1140
19. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
20. Naumann RW, Alvarez RD, Omura GA, et al: A phase 1 study of paclitaxel and cisplatin with escalating doses of doxorubicin in patients with previously untreated epithelial ovarian cancer. Proc Am Soc Clin Oncol 16:374a, 1997 (abstr 1333)
21. Hill ME, Moore J, Johnston SR, et al: G-CAT (G-CSF, cis/ carboplatin, Adriamycin® and Taxol®) for advanced ovarian cancer: Active but toxic. Proc Am Soc Clin Oncol 16:371a, 1997 (abstr 1321)
22. Flemming GF, Fowler JM, Waggoner SE, et al: Phase I trial of escalating doses of paclitaxel (TAX) combined with fixed doses of cisplatin (CIS) and doxorubicin (DOX) in patients with advanced gynecologic malignancies: A Gynecologic Oncology Group (GOG) trial. Proc Am Soc Clin Oncol 17:361a, 1998 (abstr 1393)
23. Lissoni A, Sessa C, Gabriele A, et al: Cisplatin, epirubicin and paclitaxel in uterine adenocarcinoma. Proc Am Soc Clin Oncol 16: 373a, 1997 (abstr 1329)
24. Dimipoulos MA, Papadimitriou CA, Akrivos T, et al: Paclitaxel, cisplatin and epirubicin with G-CSF for newly diagnosed patients with epithelial ovarian cancer. Proc Am Soc Clin Oncol 16:369a, 1997 (abstr 1313)
25. Greggi S, Benedetti-Panici P, Amoroso M, et al: Phase I trial of dose-escalated epirubicin (E), and paclitaxel (T), in combination with cisplatin (P) + G-CSF in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 17:366a, 1998 (abstr 1411)
26. Brunetti I, Tanganelli L, Romanini A, et al: Epidoxorubicin (EPIDOX), carboplatin (CBDCA) and paclitaxel (PTX) in advanced epithelial ovarian cancer (AEOC). Proc Am Soc Clin Oncol 17:350a, 1998 (abstr 1350)
27. Kristensen GB, Trope C: Carboplatinum, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer. Gynecol Oncol 68:117, 1998 (abstr 184)
28. Bookmann MA, McGuire WP III, Kilpatrick D, et al: Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902, 1996